Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
Role of Mirabegron and Carvedilol in treatment of ulcerative colitis
- At: Seville (Spain) (2022)
- Type: Poster
- Poster code: HMI-009
- By: EL-MARAGHY, Nabila (Faculty of Pharmacy, Future University In Egypt, Egypt)
- Co-author(s): Prof Nabila El-maraghy, Professor Of Pharmacology And Vice Dean Of Community Services And Enviromental Affairs (Faculty of Pharmacy, Future University In Egypt, Cairo, Egypt)
Ms. Salma Nasser (Faculty of Pharmacy, Future University In Egypt, Cairo, Egypt)
Prof. Dalaal M. Abdallah (Faculty of Pharmacy, Cairo University, Cairo, Egypt)
Prof. Kawkab A. Ahmed (Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt)
Ass. Prof. Yousra Abdel-Mottaleb (Faculty of Pharmacy, Future University In Egypt, Cairo, Egypt)
Prof. Hanan S. El-Abhar (Faculty of Pharmacy, Future University In Egypt, Cairo, Egypt) - Abstract:
Background: Scarce studies evaluated the impact of adrenoceptor modulators against ulcerative colitis; nonetheless, the therapeutic potential and anti-colitic mechanisms of mirabegron, a β3-adrenoreceptor (AR) agonist and/or carvedilol, a nonselective β-AR antagonist, are not unveiled.
Purpose: Investigation of the possible role/mechanism of.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023